Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249964
Status:
COMPLETED
Last Update Posted:
2016-01-20
First Post:
2005-11-03
Brief Title:
Combination Paclitaxel Carboplatin and Temozolomide
Sponsor:
New Mexico Cancer Care Alliance
Organization:
New Mexico Cancer Care Alliance
Study Overview
Official Title:
Phase I Dose Finding Clinical Trial of Combination Paclitaxel Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response
Detailed Description:
The objective of the research study is to test a combination of drugs to treat small cell lung cancer which has spread beyond the lungs extensive cancer or come back after earlier treatment recurrent cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None